Abstract
Despite advances in hepatocellular carcinoma (HCC) treatment in recent years, HCC remains as the third cause of cancer-related death worldwide. Thus, there is an urgent need to search for biomarkers for the early diagnosis of the disease. Lipidomics techniques associated with mass spectrometry may improve current knowledge on mechanisms involved in the HCC onset and progression with poten…